Bluebird Bio Files for FDA Approval of Gene Therapy Treatment for Sickle Cell Disease

Bluebird Bio has submitted an application to the FDA for approval of its gene therapy to treat sickle cell disease.
The company is seeking priority review, which could speed up the approval process.
The therapy aims to treat sickle cell disease by delivering a correct copy of the gene into patients' cells.
In a clinical trial, the treatment resolved pain crises for all 25 evaluated subjects.
While the therapy shows promise, it still faces questions about potential risks and safety concerns.